In a significant global health milestone, the World Health Organization (WHO) has announced the inclusion of a new set of medicines for the treatment of obesity and diabetes in its Essential Medicines List (EML). This marks the first time that drugs targeting obesity, alongside treatments for type 2 diabetes, have been given such recognition by the United Nations health agency. The decision is expected to reshape how governments and health systems worldwide address the rising burden of chronic diseases linked to lifestyle, diet, and metabolic disorders.
Expanding the Essential Medicines List
The WHO’s EML is a vital catalogue of medicines that the organization believes should be available in every functioning health system around the world. Updated every two years, the list guides national health authorities, procurement agencies, and international donors in prioritizing the most cost-effective and impactful therapies.
The updated list now includes 523 medicines for adults and 374 for children. Among these additions are drugs targeting cancer, cystic fibrosis, and—most notably—obesity and type 2 diabetes. WHO emphasized that the decision is not just about adding new therapies but about closing treatment gaps, especially in low- and middle-income countries where access to advanced medications has historically been limited.
GLP-1 Drugs: A New Frontier
At the heart of this update is the recognition of GLP-1 receptor agonists, a class of drugs originally developed for diabetes but increasingly used in the treatment of obesity. These medicines mimic the action of a natural hormone, glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar, reduce appetite, and promote weight loss.
Notable branded examples include Ozempic (semaglutide) and Mounjaro (tirzepatide), which have gained widespread global attention in recent years. While often associated with high prices and limited availability, WHO has stressed the need for affordable generic versions of these drugs to be made available, particularly in developing nations.
The organization’s statement noted:
“Making generic GLP-1 drugs available for people in developing countries will be a game-changer for diabetes and obesity management.”
Why This Matters
The global burden of diabetes and obesity has been growing at alarming rates. WHO estimates reveal:
- Over 800 million people worldwide live with diabetes, primarily type 2 diabetes.
- More than 1 billion people are affected by obesity, including children, adolescents, and adults.
- In 2021 alone, obesity-related conditions contributed to the deaths of over 3.7 million people.
This figure, WHO emphasized, exceeds the combined annual death toll from malaria, tuberculosis, and HIV/AIDS—highlighting the severity of the crisis.
Focus on Patients with Multiple Health Risks
The newly added GLP-1 drugs are recommended not for all individuals with diabetes but specifically for patients who face additional complications. These include individuals with:
- Type 2 diabetes alongside cardiovascular disease,
- Patients with kidney disease, or
- Patients suffering from obesity alongside diabetes.
By targeting those most at risk, WHO aims to maximize the impact of these medicines while ensuring that resources are used efficiently in health systems with limited budgets.
Barriers to Access
While the inclusion of GLP-1 drugs on the Essential Medicines List is a landmark decision, challenges remain. Currently, branded GLP-1 drugs like Ozempic and Mounjaro are prohibitively expensive in many parts of the world. Even in wealthier countries, shortages and high demand have made access difficult.
WHO is calling on pharmaceutical companies and generic drug manufacturers to step up and ensure equitable supply of affordable versions. Without this, the benefits of adding these drugs to the list may remain out of reach for much of the global population.
A Shift in Public Health Priorities
The inclusion of obesity drugs is particularly noteworthy because it signals a shift in how obesity is perceived. For decades, obesity was often dismissed as merely a lifestyle issue, rather than a chronic disease requiring medical treatment. WHO’s move underscores the reality that obesity is a complex health condition linked to serious illnesses such as:
- Type 2 diabetes,
- Cardiovascular diseases,
- Certain cancers,
- Respiratory illnesses, and
- Reduced life expectancy.
By listing obesity drugs as “essential,” WHO is essentially urging governments worldwide to treat obesity with the same urgency as other life-threatening conditions.
Global Health Implications
The ripple effects of this decision are likely to be far-reaching:
- Policy Guidance for Governments: Many national health systems rely on WHO’s list when deciding which medicines to subsidize or provide through public healthcare programs.
- Boost for Research and Innovation: Recognizing obesity and diabetes medicines as essential may encourage further research, particularly in developing cost-effective formulations.
- Reduction in Stigma: Official recognition of obesity as a treatable condition could help reduce the stigma faced by millions of people struggling with weight-related health issues.
- Improved Preventive Care: By addressing obesity medically, healthcare systems may also push harder on preventive measures, such as healthy diets, exercise programs, and public awareness campaigns.
The Road Ahead
WHO officials have described the new list as a “major advancement for global health systems.” However, they caution that simply listing a drug does not guarantee its widespread availability. Implementation will depend on the commitment of governments, partnerships with international donors, and cooperation from pharmaceutical companies.
For developing countries, the key challenge will be affordability. Without price reductions or support from international financing programs, the benefits of these breakthrough drugs may remain confined to wealthier nations.
Conclusion
The World Health Organization’s decision to add obesity and type 2 diabetes drugs—specifically GLP-1 receptor agonists—to its Essential Medicines List is a landmark moment in public health. By recognizing these therapies as critical to functioning health systems, WHO is sending a powerful message about the urgency of tackling obesity and diabetes on a global scale.
With over 1.8 billion people worldwide affected by these conditions and millions of lives lost each year, the move is both timely and necessary. The next challenge lies in ensuring that these life-saving drugs are not just listed as “essential,” but are also made accessible, affordable, and available to the people who need them most, regardless of geography or income.
